Subscribe to our Newsletters !!
Alcohol-based solvents and cleaning agents are pop
Biotech Fluidics offers a range of non-invasive fl
The recent rabies death of an 11 year old Canadian
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Micro
BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca, the German biotech group said on Monday.
The supply tally, up from more than 700 million doses announced by the biotech firm in June, compares with AstraZeneca saying late last month that it and manufacturing partner Serum Institute of India had supplied a billion doses to 170 countries at the time.
Pfizer late last month raised its forecast for its share of 2021 vaccine sales to $33.5 billion.
Still, it reiterated plans to start testing a vaccine adjusted to the highly infectious Delta variant of the virus on humans this month, part of a “comprehensive strategy to address variants, should the need arise in the future”.
